UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~November 310, 2025

IMMUNOVANT, INC.

(Exact name of Registrant as specified in its Charter)


Delaware		001-38906	83-2771572
(State or other jurisdiction of incorporation or organization)		(Commission File Number)	(IRS Employer Identification No.)

320 West 37th Street
New York,	NY		10018
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (917) 580-3099

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

IMVT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.0102. ~~Regulation~~Results FDof ~~Disclosure.~~Operations and Financial Condition

On ~~September~~November 310, 2025, Immunovant, Inc., (or the “Company”), issued a press release ~~providing~~announcing anits ~~update~~financial onresults for its ~~Graves’~~fiscal ~~Disease~~second ~~(“GD”)~~quarter ~~development~~and ~~program~~six months ended September 30, 2025. A copy of the press release is ~~attached~~furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information ~~furnished~~contained ~~under~~in this Item 72.0102, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, oras ~~the Exchange Act~~amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, oras ~~the Securities Act~~amended. The information in this Item 72.~~01,~~02 ~~including Exhibit 99.1,~~ shall not be ~~deemed~~ incorporated by reference ~~into~~in any ~~other~~ filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 8.01. Other Events.

On September 3, 2025, the Company posted a presentation regarding the update on its GD proof-of-concept study on the “Presentations” page of its investor relations website at https://www.immunovant.com/investors and will host a conference call and webcast to discuss the remission data from the GD trial at 4:30 p.m. E.D.T. A copy of the presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The contents of the Company’s website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release, dated ~~September~~November 310, 2025.
99.2						Presentation, dated September 3, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUNOVANT, INC.
	By:	/s/ Tiago Girao
		Tiago Girao
		Chief Financial Officer
Date: September 3, 2025
Date: November 10, 2025

Filing Compare · Immunovant, Inc.